Skip to content
2000
Volume 21, Issue 6
  • ISSN: 1573-403X
  • E-ISSN: 1875-6557

Abstract

Introduction

Advances in cardiac implanted electronic devices (CIED) have significantly improved outcomes for patients with heart failure. However, there is a bereft of recent real-world data on the relative effectiveness of cardiac resynchronization therapy with pacing and defibrillator (CRT-D) and continuous resynchronization therapy with pacing (CRT-P) in patients with nonischemic cardiomyopathy (NICM). We hypothesized that the addition of defibrillation therapy in patients with NICM would offer no significant benefit.

Methods

We searched the National Readmissions Database (NRD) from 2016-2020 to identify hospitalizations with NICM using appropriate ICD-10 diagnosis and procedure codes. The cohort was further divided into groups with NICM and CRT-D implantation and NICM with CRT-P implantation.

Results and Discussion

Our final cohort included 8,801 hospitalizations with NICM and CRT-D implantation and 3,399 hospitalizations with NICM and CRT-P implantation. Propensity matching was performed using comorbidities through multivariate logistic regression. Two thousand nine hundred seventeen hospitalizations were included in each of the two groups, CRT-D and CRT-P. Analysis of the propensity-matched cohorts at 180 days revealed a trend toward lower heart failure readmission, all-cause readmission, and all-cause mortality rates in the group with CRT-P implantation. However, there was no difference noted in the 180-day hazard ratios of HF readmission [1.08 (0.98-1.19); = 0.1], all-cause readmission [1.04 (0.87-1.12); = 0.23], and all-cause mortality [0.83 (0.58-1.19); = 0.32].

Conclusion

It was found that NICM patients with CRT-D have a trend towards higher HF readmissions, all-cause readmission, and all-cause mortality compared to those with CRT-P, but no significant difference was noted in hazard ratios. The findings of our study raise further questions about the need for defibrillator therapy in patients with NICM and merit further studies to better select candidates for each of these therapies.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccr/10.2174/011573403X345244250217052010
2025-03-03
2025-10-12

  • From This Site

    /content/journals/ccr/10.2174/011573403X345244250217052010
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. van WalravenC. JenningsA. ForsterA.J. A meta‐analysis of hospital 30‐day avoidable readmission rates.J. Eval. Clin. Pract.20121861211121810.1111/j.1365‑2753.2011.01773.x 22070191
     [Google Scholar]
  2. HeidenreichP.A. AlbertN.M. AllenL.A. Forecasting the impact of heart failure in the United States: A policy statement from the American Heart Association.Circ. Heart Fail.20136360661910.1161/HHF.0b013e318291329a 23616602
     [Google Scholar]
  3. ViraniS.S. AlonsoA. BenjaminE.J. Heart disease and stroke statistics—2020 update: A report from the American Heart Association.Circulation20201419e139e59610.1161/CIR.0000000000000757 31992061
     [Google Scholar]
  4. YancyC.W. JessupM. BozkurtB. 2013 ACCF/AHA guideline for the management of heart failure.J. Am. Coll. Cardiol.20136216e147e23910.1016/j.jacc.2013.05.019 23747642
     [Google Scholar]
  5. ClelandJ.G.F. DaubertJ.C. ErdmannE. The effect of cardiac resynchronization on morbidity and mortality in heart failure.N. Engl. J. Med.2005352151539154910.1056/NEJMoa050496 15753115
     [Google Scholar]
  6. BristowM.R. SaxonL.A. BoehmerJ. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.N. Engl. J. Med.2004350212140215010.1056/NEJMoa032423 15152059
     [Google Scholar]
  7. AbrahamW.T. FisherW.G. SmithA.L. Cardiac resynchronization in chronic heart failure.N. Engl. J. Med.2002346241845185310.1056/NEJMoa013194 12063368
     [Google Scholar]
  8. KøberL. ThuneJ.J. NielsenJ.C. Defibrillator implantation in patients with nonischemic systolic heart failure.N. Engl. J. Med.2016375131221123010.1056/NEJMoa1602823 27571011
     [Google Scholar]
  9. DoranB. MeiC. VarosyP.D. The addition of a defibrillator to resynchronization therapy decreases mortality in patients with nonischemic cardiomyopathy.JACC Heart Fail.20219643944910.1016/j.jchf.2021.03.005 33992570
     [Google Scholar]
  10. GuH. SidhuB.S. FangL. First-phase ejection fraction predicts response to cardiac resynchronization therapy and adverse outcomes.JACC Cardiovasc. Imaging202114122275228510.1016/j.jcmg.2021.05.007 34886993
     [Google Scholar]
  11. JaniC. AroraS. ZuzekZ. Impact of catheter ablation in patients with atrial flutter and concurrent heart failure.Heart Rhythm O2202021536310.1016/j.hrto.2020.01.001 34113905
     [Google Scholar]
  12. SahashiY. KunoT. TanakaY. PassmanR. BriasoulisA. MalikA.H. The 30-day readmission rate of same-day discharge protocol following catheter ablation for atrial fibrillation: A propensity score-matched analysis from National Readmission Database.Europace202224575576110.1093/europace/euab031 34904164
     [Google Scholar]
  13. TripathiA. AbbottJ.D. FonarowG.C. Thirty-day readmission rate and costs after percutaneous coronary intervention in the United States: A national readmission database analysis.Circ. Cardiovasc. Interv.20171012e00592510.1161/CIRCINTERVENTIONS.117.005925
     [Google Scholar]
  14. AroraS. JaswaneyR. JaniC. Catheter ablation for atrial fibrillation in patients with concurrent heart failure.Am. J. Cardiol.2020137455410.1016/j.amjcard.2020.09.035 33002464
     [Google Scholar]
  15. LamS.K.H. OwenA. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials.BMJ2007335762692592810.1136/bmj.39343.511389.BE 17932160
     [Google Scholar]
  16. McMurrayJ.J.V. PackerM. DesaiA.S. Angiotensin-neprilysin inhibition versus enalapril in heart failure.N. Engl. J. Med.201437111993100410.1056/NEJMoa1409077 25176015
     [Google Scholar]
  17. NassifM.E. WindsorS.L. TangF. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: The DEFINE-HF trial.Circulation2019140181463147610.1161/CIRCULATIONAHA.119.042929 31524498
     [Google Scholar]
  18. McMurrayJ.J.V. SolomonS.D. InzucchiS.E. Dapagliflozin in patients with heart failure and reduced ejection fraction.N. Engl. J. Med.2019381211995200810.1056/NEJMoa1908650 31535829
     [Google Scholar]
  19. PackerM. AnkerS.D. ButlerJ. Cardiovascular and renal outcomes with empagliflozin in heart failure.N. Engl. J. Med.2020383151413142410.1056/NEJMoa2022190 32865377
     [Google Scholar]
  20. AnkerS.D. ButlerJ. FilippatosG. Empagliflozin in heart failure with a preserved ejection fraction.N. Engl. J. Med.2021385161451146110.1056/NEJMoa2107038 34449189
     [Google Scholar]
  21. TurakhiaM.P. CaoM. FischerA. Reduced mortality associated with quadripolar compared to bipolar left ventricular leads in cardiac resynchronization therapy.JACC Clin. Electrophysiol.20162442643310.1016/j.jacep.2016.02.010 29759861
     [Google Scholar]
  22. OscaJ. AlonsoP. CanoO. The use of multisite left ventricular pacing via quadripolar lead improves acute haemodynamics and mechanical dyssynchrony assessed by radial strain speckle tracking: initial results.Europace201618456056710.1093/europace/euw289 26333378
     [Google Scholar]
  23. WangC.L. WuC.T. YehY.H. Left bundle-branch block contraction patterns identified from radial-strain analysis predicts outcomes following cardiac resynchronization therapy.Int. J. Cardiovasc. Imaging201733686987710.1007/s10554‑017‑1192‑3 28150083
     [Google Scholar]
  24. KatbehA. Van CampG. BarbatoE. Cardiac resynchronization therapy optimization: A comprehensive approach.Cardiology2019142211612810.1159/000501920 31117077
     [Google Scholar]
  25. Brunet-BernardA. MaréchauxS. FauchierL. Combined score using clinical, electrocardiographic, and echocardiographic parameters to predict left ventricular remodeling in patients having had cardiac resynchronization therapy six months earlier.Am. J. Cardiol.2014113122045205110.1016/j.amjcard.2014.03.027 24793667
     [Google Scholar]
  26. AnandI.S. CarsonP. GalleE. Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: Results from the comparison of medical therapy, pacing and defibrillation in heart failure (companion) trial.Circulation2009119796997710.1161/CIRCULATIONAHA.108.800598 19204305
     [Google Scholar]
  27. Laish-FarkashA. BruohaS. KatzA. Morbidity and mortality with cardiac resynchronization therapy with pacing vs. with defibrillation in octogenarian patients in a real-world setting.Europace20171981357136310.1093/europace/euw349 27733457
     [Google Scholar]
  28. HsuJ.C. SolomonS.D. BourgounM. Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: The MADIT-CRT study.J. Am. Coll. Cardiol.201259252366237310.1016/j.jacc.2012.02.067 22698490
     [Google Scholar]
  29. RussoA.M. StainbackR.F. BaileyS.R. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: A report of the American College of Cardiology Foundation Appropriate use Criteria Task Force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance.J. Am. Coll. Cardiol.201361121318136810.1016/j.jacc.2012.12.022 23453819
     [Google Scholar]
  30. SchaerB.A. OsswaldS. Di ValentinoM. Close connection between improvement in left ventricular function by cardiac resynchronization therapy and the incidence of arrhythmias in cardiac resynchronization therapy-defibrillator patients.Eur. J. Heart Fail.201012121325133210.1093/eurjhf/hfq188 20923856
     [Google Scholar]
  31. Van BovenN. BogaardK. RuiterJ. Functional response to cardiac resynchronization therapy is associated with improved clinical outcome and absence of appropriate shocks.J. Cardiovasc. Electrophysiol.201324331632210.1111/jce.12087 23210664
     [Google Scholar]
  32. SchrageB. LundL.H. MelinM. Cardiac resynchronization therapy with or without defibrillator in patients with heart failure.Europace2022241485710.1093/europace/euab204 34486653
     [Google Scholar]
  33. CevikC. Perez-VerdiaA. NugentK. Implantable cardioverter defibrillators and their role in heart failure progression.Europace200911671071510.1093/europace/eup124 19357142
     [Google Scholar]
  34. KramerD.B. NormandS.L.T. VolyaR. HatfieldL.A. Facility-level variation and clinical outcomes in use of cardiac resynchronization therapy with and without an implantable cardioverter-defibrillator.Circ. Cardiovasc. Qual. Outcomes20181112e00476310.1161/CIRCOUTCOMES.118.004763 30562069
     [Google Scholar]
  35. ÇinierG. HayıroğluM.İ. KolakZ. The value of C‐reactive protein‐to‐albumin ratio in predicting long‐term mortality among HFrEF patients with implantable cardiac defibrillators.Eur. J. Clin. Invest.2021518e1355010.1111/eci.13550 33778950
     [Google Scholar]
  36. ÇinierG. HayıroğluM.İ. PayL. Prognostic nutritional index as the predictor of long‐term mortality among HFrEF patients with ICD.Pacing Clin. Electrophysiol.202144349049610.1111/pace.14170 33438766
     [Google Scholar]
/content/journals/ccr/10.2174/011573403X345244250217052010
Loading
Trends in Readmissions Rates and Mortality after Cardiac Resynchronization Therapy in Patients with Nonischemic Cardiomyopathy
Curr. Cardiol. Rev. 21, e1573403X345244 (2025); https://doi.org/10.2174/011573403X345244250217052010
/content/journals/ccr/10.2174/011573403X345244250217052010
/content/journals/ccr/10.2174/011573403X345244250217052010
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): cardiac implanted electronic devices (CIED); cardiac resynchronization therapy; defibrillator; heart failure readmission; medication management; Nonischemic cardiomyopathy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test